These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 29487419)

  • 1. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.
    McKinnon T; Venier R; Yohe M; Sindiri S; Gryder BE; Shern JF; Kabaroff L; Dickson B; Schleicher K; Chouinard-Pelletier G; Menezes S; Gupta A; Zhang X; Guha R; Ferrer M; Thomas CJ; Wei Y; Davani D; Guidos CJ; Khan J; Gladdy RA
    Oncogene; 2018 May; 37(20):2630-2644. PubMed ID: 29487419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
    Li SQ; Cheuk AT; Shern JF; Song YK; Hurd L; Liao H; Wei JS; Khan J
    PLoS One; 2013; 8(10):e76551. PubMed ID: 24124571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma.
    Liu T; Sun Q; Li Q; Yang H; Zhang Y; Wang R; Lin X; Xiao D; Yuan Y; Chen L; Wang W
    Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
    Taylor JG; Cheuk AT; Tsang PS; Chung JY; Song YK; Desai K; Yu Y; Chen QR; Shah K; Youngblood V; Fang J; Kim SY; Yeung C; Helman LJ; Mendoza A; Ngo V; Staudt LM; Wei JS; Khanna C; Catchpoole D; Qualman SJ; Hewitt SM; Merlino G; Chanock SJ; Khan J
    J Clin Invest; 2009 Nov; 119(11):3395-407. PubMed ID: 19809159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma.
    Fiorito E; Szybowska P; Haugsten EM; Kostas M; Øy GF; Wiedlocha A; Singh S; Nakken S; Mælandsmo GM; Fletcher JA; Meza-Zepeda LA; Wesche J
    Br J Cancer; 2022 Nov; 127(11):1939-1953. PubMed ID: 36097178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
    Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
    Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.
    Crose LE; Etheridge KT; Chen C; Belyea B; Talbot LJ; Bentley RC; Linardic CM
    Clin Cancer Res; 2012 Jul; 18(14):3780-90. PubMed ID: 22648271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insight into ponatinib resistance mechanisms in rhabdomyosarcoma caused by the mutations in FGFR4 tyrosine kinase using molecular modeling strategies.
    Wu C; Chen X; Chen D; Xia Q; Liu Z; Li F; Yan Y; Cai Y
    Int J Biol Macromol; 2019 Aug; 135():294-302. PubMed ID: 31128178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models.
    Timpanaro A; Piccand C; Dzhumashev D; Anton-Joseph S; Robbi A; Moser J; Rössler J; Bernasconi M
    J Exp Clin Cancer Res; 2023 Nov; 42(1):293. PubMed ID: 37924157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling.
    Zhu DS; Dong JY; Xu YY; Zhang XT; Fu SB; Liu W
    Med Sci Monit; 2020 Aug; 26():e927106. PubMed ID: 32804918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
    Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma.
    Tian M; Wei JS; Shivaprasad N; Highfill SL; Gryder BE; Milewski D; Brown GT; Moses L; Song H; Wu JT; Azorsa P; Kumar J; Schneider D; Chou HC; Song YK; Rahmy A; Masih KE; Kim YY; Belyea B; Linardic CM; Dropulic B; Sullivan PM; Sorensen PH; Dimitrov DS; Maris JM; Mackall CL; Orentas RJ; Cheuk AT; Khan J
    Cell Rep Med; 2023 Oct; 4(10):101212. PubMed ID: 37774704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
    J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis.
    Xiao Y; Yu Y; Jiang P; Li Y; Wang C; Zhang R
    Cell Oncol (Dordr); 2020 Aug; 43(4):669-680. PubMed ID: 32382996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of mTOR Inhibitors in Growth Hormone-Producing Pituitary Adenomas Harboring Different FGFR4 Genotypes.
    Jalali S; Monsalves E; Tateno T; Zadeh G
    Endocrinology; 2016 Sep; 157(9):3577-87. PubMed ID: 27267848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
    Hebron KE; Wan X; Roth JS; Liewehr DJ; Sealover NE; Frye WJE; Kim A; Stauffer S; Perkins OL; Sun W; Isanogle KA; Robinson CM; James A; Awasthi P; Shankarappa P; Luo X; Lei H; Butcher D; Smith R; Edmondson EF; Chen JQ; Kedei N; Peer CJ; Shern JF; Figg WD; Chen L; Hall MD; Difilippantonio S; Barr FG; Kortum RL; Robey RW; Vaseva AV; Khan J; Yohe ME
    Clin Cancer Res; 2023 Jan; 29(2):472-487. PubMed ID: 36322002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR4 signaling couples to Bim and not Bmf to discriminate subsets of alveolar rhabdomyosarcoma cells.
    Wachtel M; Rakic J; Okoniewski M; Bode P; Niggli F; Schäfer BW
    Int J Cancer; 2014 Oct; 135(7):1543-52. PubMed ID: 24550147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.
    Wong K; Di Cristofano F; Ranieri M; De Martino D; Di Cristofano A
    Endocr Relat Cancer; 2019 Apr; 26(4):425-436. PubMed ID: 30699064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.